6/3/2013 10:14:46 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that
new data supporting further evaluation of crolibulin were presented at the
Annual Meeting of the American Society of Clinical Oncology (ASCO 2013), taking
place May 31 to June 4, 2013 at the McCormick Place Convention Center in
Chicago. Crolibulin is EpiCept’s small molecule vascular disruption agent (VDA)
and apoptosis inducer for the treatment of patients with advanced solid tumors
and lymphomas. Crolibulin is a microtubule destabilizing agent that disrupts
vascular endothelial cells, and in turn, blood flow to tumors.
Help employers find you! Check out all the jobs and post your resume.
comments powered by